Altria Group names CFO Salvatore Mancuso as its incoming CEO, accelerating its smoke-free transition while taking a massive impairment charge on past investments, signaling a sharp strategic reassessment.
Citi analyst Geoff Meacham raised his price target on Bristol-Myers Squibb (BMY) to $60, citing a more favorable setup for the sector. The move comes as the drugmaker also announces a partnership with Microsoft to leverage AI for earlier lung cancer detection.
Altria Group (MO) posted stronger-than-expected Q4 revenue, driven by its core tobacco brands and oral nicotine products, but saw its shares fall as profit margins contracted sharply. The company is betting on a national rollout of its ON! Plus pouches and manufacturing upgrades to fuel its smoke-free future.
Israel announces a limited reopening of the Rafah border crossing between Gaza and Egypt this Sunday, permitting the movement of people under strict security protocols for the first time since its capture in May 2024.
Honeywell International posts a robust Q4 with record orders and backlog, while announcing an accelerated timeline to spin off its core Aerospace business as a standalone public company by late 2026, a move set to redefine its investment profile.
Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.
Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.
French biopharma firm Inventiva (ENXTPA:IVA) has delivered a stunning 126% total return to shareholders over the past year, sharply contrasting with losses over a three-year horizon. As the stock experiences short-term pullbacks, analysts debate whether its current €5.23 price reflects future promise or present hype, with a key drug candidate hanging in the balance.
Amneal Pharmaceuticals' shares have surged over 64% in the past year, prompting investors to question if the rally still has room to run. A closer look at valuation metrics suggests the generic drugmaker may still be trading at a significant discount to its intrinsic value.
The thrill of the hunt for luxury bargains is fading for American shoppers as Saks Global closes dozens of off-price physical stores. Experts explain the deep-seated psychology behind bargain hunting and what the retail landscape loses with these closures.
Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
London-based trading giant IG Group has completed its takeover of Australian cryptocurrency exchange Independent Reserve, following regulatory approval in Singapore. The move paves the way for the launch of regulated crypto services in key markets including Singapore, Australia, and the UAE by late 2026.
Saks Global moves to close over 60 Off 5th locations as part of Chapter 11 proceedings, signaling a strategic retreat from the competitive off-price segment to focus on core luxury brands.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.
The acquisition, set to finalize in early 2026 pending approvals, will merge European and American production powerhouses into an entity overseeing nearly 100 companies across 15 countries.
In a significant departure from its longstanding position, an Israeli military official has acknowledged a death toll in Gaza close to 70,000, aligning with figures long maintained by Palestinian health authorities. This admission follows over two years of war and persistent international scrutiny over casualty counts.
Nubank, the Latin American fintech leader, has secured conditional approval from the OCC for a U.S. national bank charter, setting an 18-month timeline to launch and challenging incumbent banks with its digital-first model.
Israel announces the Rafah border crossing will reopen this Sunday for limited travel between Gaza and Egypt, marking a significant shift in access for the enclave's 2 million residents after an eight-month Israeli control of the vital gateway.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
